GLP-1 Receptor Agonists Offer Transformative Therapeutic Opportunity for Polyendocrine Metabolic Ovarian Syndrome

Polyendocrine metabolic ovarian syndrome (PMOS) is a highly challenging condition characterized by the convergence of reproductive dysfunction, obesity, insulin resistance, and chronic inflammation. Current management often remains fragmented across metabolic, reproductive, and psychological domains, failing to address the holistic pathology. The emergence of glucagon-like peptide-1 receptor agonists (GLP-1RAs) presents a significant opportunity to target the complex endocrine and reproductive disturbances that underpin PMOS more comprehensively.

This descriptive clinical review examines the implications of glucagon-like peptide-1 receptor agonists (GLP-1RAs) for the fertility of women with polyendocrine metabolic ovarian syndrome (PMOS). It synthesizes current understanding of GLP-1RA mechanisms in addressing the complex endocrine and reproductive disturbances characteristic of PMOS, aiming to frame their therapeutic potential. The review utilizes a descriptive clinical framework to highlight the transformative opportunities these agents present.

This review concludes that glucagon-like peptide-1 receptor agonists (GLP-1RAs) represent a significant therapeutic advancement for women with polyendocrine metabolic ovarian syndrome (PMOS). They are positioned to address the multifaceted pathology of PMOS, including obesity, insulin resistance, reproductive dysfunction, and chronic inflammation. The authors highlight GLP-1RAs' potential to integrate fragmented management approaches across metabolic, reproductive, and psychological domains.

The core finding emphasizes GLP-1RAs' capacity to mitigate the complex endocrine and reproductive disturbances that define PMOS, offering a more holistic treatment strategy.